Aimovig

Aimovig

erenumab

Manufacturer:

Novartis

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Erenumab
Indications/Uses
Prophylaxis of migraine in adults who have at least 4 migraine days per mth.
Dosage/Direction for Use
SC 70 mg every 4 wk administered in the abdomen, thigh or outer area of the upper arm. Some patients may benefit from 140 mg every 4 wk.
Contraindications
Special Precautions
Discontinue treatment if serious or severe hypersensitivity reaction occurs. Patients w/ major CVD. Pregnancy & lactation. Ped patients.
Adverse Reactions
Hypersensitivity reactions including anaphylaxis, angioedema, rash, swelling/oedema & urticaria; constipation; pruritus; muscle spasms; inj site reactions.
ATC Classification
N02CD01 - erenumab ; Belongs to the class of calcitonin gene-related peptide (CGRP) antagonists preparations. Used to relieve migraine.
Presentation/Packing
Form
Aimovig inj 70 mg/mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in